logo
5 Things to Do When You Wake Up to Help Lower Cholesterol, According to Experts

5 Things to Do When You Wake Up to Help Lower Cholesterol, According to Experts

Yahoo17-02-2025

Reviewed by Dietitian Karen Ansel, M.S., RDN
High cholesterol is a risk factor for heart disease and stroke. But you might not even know you have it until a doctor runs a blood test. After all, high cholesterol doesn't have any specific symptoms that you can feel or see. Yet, nearly 25 million American adults are living with it.
But here's the good news: There are easy diet and lifestyle steps that may help you manage high cholesterol. And what better time to implement those changes than when you first wake up in the morning? So, we asked heart-health experts their top morning tips to keep cholesterol in check. Here's what they told us.
The one piece of advice that all our experts wholeheartedly recommend is to start your day with plants. Plant-based foods like fruits, vegetables, whole grains, legumes, nuts and seeds offer a host of cholesterol-busting benefits. For starters, they're high in cholesterol-lowering fiber, plus they're packed with antioxidants, vitamins and minerals, explains Mary Greene, M.D., a board-certified cardiologist with Manhattan Cardiology in New York City and a contributor to LabFinder.com. At the same time, they're also naturally low in saturated fat, she says.
That's not the only way a plant-rich breakfast can help. 'Plant sterols and stanols, found in many plant foods, can block the absorption of cholesterol in the intestines,' says Greene. Top sources include vegetable, canola and olive oils and whole grains, especially corn, rye, barley and wheat. You can also get them from avocados (one more reason to love avocado toast!). ,
Eating a fiber-rich, plant-based breakfast also helps stabilize blood sugar, which, in turn, impacts cholesterol levels. 'Consistently high blood sugar can raise bad cholesterol levels, which is something we want to avoid,' says Kimberley Rose-Francis, RDN, CDCES, LD, a Florida-based dietitian and diabetes educator in private practice. 'The fiber found in plant-based foods helps regulate the body's use of sugar and can also prevent the absorption of some dietary fats that impact cholesterol levels.'
'Including soluble fiber at breakfast is one of the most effective ways to lower LDL cholesterol,' says Veronica Rouse, RD, CDE, owner of The Heart Dietitian. What makes it so special? 'Soluble fiber binds to cholesterol particles in the digestive system and helps remove them from the body before they enter the bloodstream,' explains Rouse.
Oats are perhaps the best way to load up on soluble fiber in the morning. These filling whole grains are rich in a unique type of cholesterol-lowering fiber called beta-glucan. It's so powerful, in fact, the Food and Drug Administration allows food manufacturers to claim that consuming 3 grams of beta-glucan daily may reduce coronary heart disease risk. If you're wondering how much oatmeal you'll need to get the job done, that's just under 1 cup of dry oats.,
If oats aren't your thing, there are plenty of other soluble fiber–rich foods to choose from. Rouse recommends chia seeds, ground flaxseed and barley since they are easy to incorporate into a variety of breakfast foods. Other good choices include legumes, sweet potatoes, peas, oranges, avocados, apples and pears.
Diets high in animal foods like beef, chicken, pork, seafood, eggs and dairy increase cholesterol, says Tracy Paeschke, M.D., a Colorado-based preventive cardiologist in private practice. So, if you want to positively impact your cholesterol levels, try swapping out saturated fat–rich breakfast foods like bacon, sausage, cream cheese and butter for heart-healthy unsaturated fats. Rouse recommends monounsaturated fats from foods like avocados, almond butter and peanut butter, which can help reduce unfavorable LDL cholesterol while increasing beneficial HDL cholesterol.
If eggs are your go-to breakfast, they can still be compatible with a heart-healthy diet. Just cook them in an oil rich in unsaturated fats, like safflower, grapeseed or olive oil, instead of butter, says Rose-Francis.
Related: What's the Difference Between Saturated Fat and Unsaturated Fat?
Starting your day with a healthy breakfast isn't the only thing you can do for your cholesterol. Physical activity can positively influence cholesterol levels, and strengthen your heart while you're at it. In fact, research has found that regular exercise can decrease unfavorable LDL cholesterol and fats in the blood, known as triglycerides, while increasing beneficial HDL cholesterol.
How much exercise should you aim for? The Centers for Disease Control and Prevention recommends at least 150 minutes of moderate-intensity exercise weekly. That might sound like a lot, but broken into smaller increments, it's just 20 to 25 minutes of physical activity each morning. If you've fallen out of the exercise habit or could use some help getting started, our walking plan to help lower cholesterol levels is a great place to begin.​​
Related: The Best Time of Day to Exercise if You Struggle to Make It a Habit, According to Research
While we're more connected than ever, the constant ping of cellphone and laptop notifications can be overstimulating. No wonder we're feeling chronically stressed. Trouble is, ongoing stress can take a toll on our heart health since it increases heart rate and blood pressure. It can also prompt our bodies to release stress hormones like cortisol and adrenaline. If that happens once in a while, it's no big deal. But when it becomes the norm, this hormonal storm may increase cholesterol levels. If that weren't enough, it may also trigger the urge to stress-eat, which can make it difficult to stick with heart-healthy food choices.
Set the tone for the rest of your day by taking a few minutes in the morning (just 10 is all you need) to practice mindfulness. Before the day's frenzy takes over, practice deep breathing, meditate, journal, do yoga or quietly sip a cup of tea to ease you into your day.
If you can take your favorite mindfulness practice outside, even better. Fitting in an outdoor morning workout does double duty, lowering your cholesterol and stress levels at the same time. Plus, you're less likely to skip a workout when you're tired later on.
Making the most of your mornings is important. But there's no need for a complicated a.m. routine to lower your cholesterol. Small but impactful changes to your morning habits are a sustainable way to improve your cholesterol and heart health in the long run. So, start your day with some light exercise followed by a plant-focused breakfast that's rich in soluble fiber and contains a little bit of heart-healthy unsaturated fat. Then, before you head out the door, allow yourself a few mindful minutes. It won't just calm your mind. It will do your heart good as well!
Read the original article on EATINGWELL

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs
Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs

Yahoo

time30 minutes ago

  • Yahoo

Philip Morris International Tech Ecosystem Company Profile 2025: Digital Transformation Strategies and Innovation Programs

Philip Morris International Inc., a leading tobacco company, is committed to becoming a 100% smoke-free entity. By March 2025, 42% of revenue was from smoke-free products like IQOS and ZYN. The firm is advancing digital transformation and tech initiatives to enhance health-focused and prescription products. Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Tech Ecosystem Series: Philip Morris International Inc. - 2025" company profile has been added to offering. The report provides insights into the Philip Morris International's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives. Philip Morris International Inc. (Philip Morris) is a US-based multinational tobacco company. It produces cigarettes and a variety of smoke-free products, including e-vapor, heated tobacco, and oral smokeless products. Philip Morris aims to become a 100% smoke-free products company in the near future. As of March 31, 2025, smoke-free products accounted for 42% of Philip Morris' overall revenue. The company is also focusing on developing and commercializing oral and inhaled consumer health & wellness products, as well as inhaled prescription products for cardiovascular emergencies and pain management. IQOS and ZYN are the leading smoke-free brands of the company, while Marlboro, Parliament, Chesterfield, L&M and Philip Morris are the leading cigarette report provides information and insights into Philip Morris' tech activities, including: Insights of its digital transformation strategies and innovation programs. Overview of technology initiatives covering partnerships and product launches. Insights on each technology initiative including technology theme, objective, and benefits. Details of estimated ICT budgets. Reasons to Buy Gain insights into Philip Morris' tech operations. Gain insights into its tech strategies and innovation initiatives. Gain insights into its technology themes under focus. Gain insights into various product launches and partnerships. Key Topics Covered: Overview Digital Transformation Strategy Accelerators, Incubators, and other Innovation Programs Technology Focus Technology Initiatives Venture Arm: PM Equity Partner Partnerships Network Map ICT Budget and Contracts Key Executives For more information about this company profile visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans
AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

Yahoo

timean hour ago

  • Yahoo

AstraZeneca forms an AI deal in China; Third Harmonic advances liquidation plans

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Today, a brief rundown of news involving AstraZeneca and Third Harmonic Bio, as well as updates from UCB, UroGen Pharma and Insmed that you may have missed. AstraZeneca on Friday formed a new collaboration with Shijiazhuang City, China-based CSPC Pharmaceutical Group, this time to use the firm's AI technology to discover oral drugs for immunological diseases and other unspecified chronic conditions. CSPC will get $110 million in upfront cash and is eligible to receive up to $5.2 billion in additional development and sales milestones. The alliance builds on a 2024 deal that handed AstraZeneca an oral, lipid-lowering therapy, and deepens the British drugmaker's investment in China. In March, the company committed $2.5 billion to a research and development center in Beijing and formed collaborations with three China-based biotechs. — Ben Fidler Belgian drugmaker UCB said on Thursday that it plans to build a new biologics manufacturing plant in the U.S. UCB is currently running a "feasibility study" to determine the ideal U.S. location for the coming facility, but said in a statement that, once operational, it should create about 300 jobs in biologics manufacturing and have an economic impact of around $5 billion. The company currently employs close to 2,000 workers in the U.S. — Ben Fidler Stockholders of Third Harmonic Bio have voted in support of a liquidation plan expected to see them recoup anywhere from $5.30 to $5.44 for each share they own. The company also said Thursday that it's beginning an auction for an experimental drug for chronic hives that's ready for Phase 2 testing. Proceeds from that auction, as well as sales of any other remaining assets, could boost stockholder payouts beyond current estimates. Third Harmonic raised $185 million in a 2022 initial public offering, but its share price plummeted shortly afterwards following a clinical setback. — Ben Fidler Insmed has raised $750 million in a public stock offering, quickly cashing in on positive Phase 2 study results that pushed its market value past $16 billion. The company on Wednesday sold 7,812,500 shares of its common stock at $96 apiece, raising more than it initially projected. Insmed shares climbed by a third this week after mid-stage results indicated its experimental drug could be superior to an inhalable pulmonary arterial hypertension medicine that's sold by United Therapeutics and could reach almost $2 billion in sales this year. The company expects to start a pair of Phase 3 trials later this year and early next. — Ben Fidler The Food and Drug Administration bypassed the advice of one of its expert panels in approving a drug Urogen Pharma has been developing for a form of bladder cancer. The therapy, a formulation of the chemotherapy mitomycin, was cleared on Thursday and will be sold as Zusduri for a recurrent type of non-muscle invasive bladder cancer. FDA advisers last month determined by a slim, 5-4 margin, that the drug's benefits didn't outweigh the risks of treatment. UroGen shares surged more than 60% since the announcement. — Ben Fidler Sign in to access your portfolio

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda
Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Yahoo

time2 hours ago

  • Yahoo

Merck Gets FDA Approval to Expand Use of Its Top-Selling Drug, Keytruda

Merck has received approval from the Food and Drug Administration to expand use of its blockbuster drug, Keytruda, to treat head and neck cancers. Studies found patients taking Keytruda can reduce the risk of head and neck cancer recurrence, progression, or death by 30% compared to current treatments. Keytruda is Merck's best-selling drug, generating more than $7 billion in revenue in the first (MRK) has received the go-ahead to expand use of its blockbuster cancer drug, Keytruda. The Food and Drug Administration (FDA) has approved Keytruda's use for adults with resectable locally advanced head and neck squamous cell carcinoma whose tumors express the protein PD-L1. The study's overall principal investigator, Dr. Ravindra Uppaluri, said the approval "represents a potentially significant shift in how we manage this disease." Dr. Uppaluri added Keytruda "has been shown to reduce the risk of recurrence, progression, or death by 30%, compared with standard of care adjuvant chemoradiotherapy or radiotherapy alone." Merck noted that it's estimated that in 2025, there will be approximately 72,680 new cases of head and neck cancer diagnosed, and more than 16,680 deaths from the disease. Keytruda is the company's best-selling drug, with first-quarter revenue of $7.2 billion, making up nearly half of its total sales. Entering Friday trading, shares of Merck were down about 18% year-to-date. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store